hLAB is a highly specialised virology and immunology laboratory offering a suite of services to support pre-clinical and clinical respiratory drug and vaccine discovery and development.
Their work includes assay development, transfer and optimization across immunology, molecular and cell-based assays, including offering extensive options in sample matrix and stability testing and stability analysis. All assays validated to FDA, EMA and ICH guidelines.
With specialists focusing on virology, immunology and molecular biology, hLAB is well equipped within our Biosafety Level 2 and 3 facilities to provide high quality data outputs to enable clients to arrive at a proof of concept, or to make a breakthrough discovery in the pathology and possible treatment of diseases with unmet medical needs.
hVIVO plc (formerly Open Orphan plc), led by Cathal Friel, is a rapidly growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and antivirals using human challenge clinical trials, providing end-to-end early clinical development services for its broad and long-standing client base of biopharma companies.
